Shares of Sana Biotechnology (NASDAQ:SANA) rallied 270% post-market on positive results from a study of the transplantation ...

BofA lowered the firm’s price target on Sana Biotechnology (SANA) to $7 from $8 and keeps a Buy rating on the shares. While political and rate ...

Zhengye Biotechnology (ZYBT) priced its initial public offering of 1.5M shares at a public offering price of $4.00 per share.

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...

Upstream's breeding technologies, which protect plants from yield-threatening diseases, have already delivered strong results ...

Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

UNITY Biotechnology (UBX) strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical ...

Anbio Biotechnology seeks IPO funding to expand in the IVD market. Discover why NNNN stock’s potential is tempered by ...

NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors ...

Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes ...